147 related articles for article (PubMed ID: 1836750)
1. Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures.
Farkas R; Ben-Efraim S; Manor Y; Zan-Bar I; Klajman A
Cancer Immunol Immunother; 1991; 34(3):181-5. PubMed ID: 1836750
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
Consoli U; El-Tounsi I; Sandoval A; Snell V; Kleine HD; Brown W; Robinson JR; DiRaimondo F; Plunkett W; Andreeff M
Blood; 1998 Mar; 91(5):1742-8. PubMed ID: 9473241
[TBL] [Abstract][Full Text] [Related]
3. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
[TBL] [Abstract][Full Text] [Related]
4. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.
Mackus WJ; Frakking FN; Grummels A; Gamadia LE; De Bree GJ; Hamann D; Van Lier RA; Van Oers MH
Blood; 2003 Aug; 102(3):1057-63. PubMed ID: 12689926
[TBL] [Abstract][Full Text] [Related]
5. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
[TBL] [Abstract][Full Text] [Related]
6. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
7. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
[TBL] [Abstract][Full Text] [Related]
8. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease.
Tötterman TH; Carlsson M; Simonsson B; Bengtsson M; Nilsson K
Blood; 1989 Aug; 74(2):786-92. PubMed ID: 2787679
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.
Cordone I; Matutes E; Catovsky D
Leukemia; 1992 Sep; 6(9):902-6. PubMed ID: 1387694
[TBL] [Abstract][Full Text] [Related]
11. CD8-positive B-cell chronic lymphocytic leukemia. A report of two cases.
Koelliker DD; Steele PE; Hurtubise PE; Flessa HC; Sheng YP; Swerdlow SH
Am J Clin Pathol; 1994 Aug; 102(2):212-6. PubMed ID: 8042591
[TBL] [Abstract][Full Text] [Related]
12. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
13. B-cell chronic lymphocytic leukaemia with CD8 expression: report of 10 cases and immunochemical analysis of the CD8 antigen.
Mulligan SP; Dao LP; Francis SE; Thomas ME; Gibson J; Cole-Sinclair MF; Wolf M
Br J Haematol; 1998 Oct; 103(1):157-62. PubMed ID: 9792303
[TBL] [Abstract][Full Text] [Related]
14. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
16. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.
Krackhardt AM; Harig S; Witzens M; Broderick R; Barrett P; Gribben JG
Blood; 2002 Jul; 100(1):167-73. PubMed ID: 12070023
[TBL] [Abstract][Full Text] [Related]
17. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis.
Aguilar-Santelises M; Loftenius A; Ljungh C; Svenson SB; Andersson B; Mellstedt H; Jondal M
Leuk Res; 1992; 16(6-7):607-13. PubMed ID: 1386130
[TBL] [Abstract][Full Text] [Related]
19. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
